Medivir AB Series B | Mutual Funds
Mutual Funds that own Medivir AB Series B
Nordea Nordic Small Cap
1,670,114
6.88%
-224,369
0.35%
04/30/2018
DFA Continental Small Company Series
169,635
0.7%
13,943
0.01%
01/31/2018
150,000
0.62%
0
0.38%
07/31/2018
Nordea 1 - Nordic Equity Small Cap Fund
119,172
0.49%
0
0.3%
07/31/2018
DFA International Core Equity Portfolio
106,690
0.44%
0
0%
04/30/2018
Nordea Institutionella Aktiefonden Sverige
103,251
0.43%
2,849
0.05%
05/31/2018
SEB Sverige Indexfond
47,686
0.2%
0
0.01%
12/31/2017
SEB Världenfond
38,751
0.16%
-7,423
0%
12/31/2017
Skandia SMART Balanserad
35,348
0.15%
0
0%
07/31/2018
Nordea Invest Nordic Small Cap
30,861
0.13%
0
0.21%
01/31/2018
| Address |
Lunastigen 7
Huddinge AB 141 44
Sweden
|
|
Employees
|
- |
| Website |
http://www.medivir.com |
| Updated |
07/08/2019 |
| Medivir AB engages in the development of pharmaceuticals products. It focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. |
